

DEAL PROFILE

GILEAD SCIENCES | KITE PHARMA

VALUES

\$10.4bn

29.0%

118.9x

TRANSACTION VALUE

SHARE PRICE PREMIUM

IEV / NTM REVENUE



KITE PHARMA, INC. (NASDAQ: KITE)

Kite Pharma, Inc. ("Kite") is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of novel cancer immunotherapy products. Kite Pharma, Inc. was founded in 2009 and is headquartered in Santa Monica, California.

IEV: \$10.4bn

LTM EBITDA: \$341.1m

LTM Revenue: \$32.1m



GILEAD SCIENCES, INC. (NASDAQGS: GILD)

Gilead Sciences, Inc. ("Gilead") discovers, develops, and commercializes medicines in the areas of unmet medical needs in Europe, North America, Asia, South America, Africa, Australia, India, and the Middle East. Gilead has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., Galapagos NV., and Spring Bank Pharmaceuticals, Inc. The company was founded in 1987 and is headquartered in Foster City, California.

IEV: \$17.9bn

LTM EBITDA: \$918m

LTM Revenue: \$3.74bn

BOURNE PARTNERS MARKET RESEARCH

Bourne Partners provides strategic and financial advisory services to clients throughout the business evolution life cycle. In order to provide the highest level of service, we routinely analyze relevant industry trends and transactions. These materials are available to our clients and partners and provide detailed insight into the pharma, pharma services, OTC, consumer health, and biotechnology sectors.

OVERVIEW

Gilead Sciences, Inc. entered into a definitive agreement to acquire Kite Pharma, Inc. for \$10.4 billion on August 27, 2017. Pursuant to the agreement, Gilead will commence a tender offer to purchase all of the issued and outstanding shares of Kite Pharma at a price of \$180 per share, net to the seller in cash, without interest. Gilead plans to finance the transaction with a combination of cash on hand, bank debt and senior unsecured notes.

HIGHLIGHTS

Kite has developed engineered cell therapies that express either a chimeric antigen receptor (CAR) or an engineered T cell receptor (TCR). Kite's most advanced therapy candidate, axicabtagene ciloleucel (axi-cel), is a CAR T therapy with treatment options for refractory aggressive non-Hodgkin lymphoma, and is awaiting an expected FDA approval in Q4 2017 in the United States and in 2018 in Europe. Gilead views this transaction as an opportunity to position the company as a global leader in oncology and cell therapy. Update: the transaction closed on October 2, 2017.